Company news
Omeros Corporation (NASDAQ:OMER) news
Every Omeros Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Omeros Corporation Reports Second Quarter 2026 Financial Results
August 12, 2026
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
August 10, 2026
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
August 3, 2026
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
June 26, 2026
Omeros Corporation Reports First Quarter 2026 Financial Results
May 13, 2026
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
May 11, 2026
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
Omeros Corporation - CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA
April 17, 2026
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
April 16, 2026
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
March 31, 2026
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
March 26, 2026
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
March 21, 2026
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
February 17, 2026
Omeros Announces First Commercial Sales of YARTEMLEA®
January 27, 2026
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
December 26, 2025
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
December 24, 2025
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibito...
December 1, 2025
Omeros Corporation Reports Third Quarter 2025 Financial Results
November 13, 2025
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
November 11, 2025
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Co...
October 16, 2025
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
October 15, 2025
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access ...
September 2, 2025
Omeros Corporation Reports Second Quarter 2025 Financial Results
August 14, 2025
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
August 11, 2025
D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Di...
July 31, 2025
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
July 25, 2025
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
June 27, 2025
Omeros Announces Webcast Details for Annual Meeting of Shareholders
June 24, 2025
Omeros Corporation Reports First Quarter 2025 Financial Results
May 15, 2025
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
May 12, 2025
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
May 12, 2025
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and...
May 6, 2025
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
April 10, 2025
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at U...
April 8, 2025
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
March 31, 2025
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
March 26, 2025
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
March 21, 2025
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Coca...
March 13, 2025
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
February 20, 2025
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
February 14, 2025
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
February 10, 2025
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
January 16, 2025
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in P...
December 19, 2024
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
December 10, 2024
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
November 21, 2024
Omeros Corporation Reports Third Quarter 2024 Financial Results
November 13, 2024
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
November 11, 2024
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
October 24, 2024
Omeros Corporation Reports Second Quarter 2024 Financial Results
August 7, 2024
Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its...
June 3, 2024